8-K: Allurion Technologies Announces $20 Million Capital Raise and Provides Business Update

Allurion Technologies is raising $20 million to fund clinical trials, commercial sales, research and development, and for working capital, while also providing an update on its business and growth strategy.

Summary

• Allurion Technologies is raising $20 million through a combination of common stock and warrants.
• The funds will be used for clinical trials, commercial sales, research and development, and general working capital.
• The company is targeting a 20% year-over-year growth in procedure volume for 2024.
• Allurion's international business generated $53 million in revenue with a 78% gross margin in 2023.
• The company expects data from its FDA AUDACITY trial by the end of 2024, which could enable entry into the $18 billion U.S. market.
• Allurion is commercializing its AI-powered digital platform globally, including in the U.S.
• The company is targeting a $54 billion obesity treatment market by 2030.
• The Allurion balloon has shown 14% total body weight loss with one balloon and 23% with two sequential balloons.
• The company has treated over 150,000 patients worldwide in over 1,500 partner clinics.
• Allurion is implementing strategic cost reductions to reduce 2024 cash burn to approximately $30 million from $64 million in 2023.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth potential and innovative technology, but also acknowledges challenges such as the need for regulatory approvals and cost reductions. The capital raise is a positive step for funding growth.

Positives

• Allurion has a large addressable market with significant growth potential.
• The company's innovative gastric balloon technology has shown strong weight loss results.
• Allurion has a strong international business with a path to profitability.
• The company is experiencing robust procedure volume growth.
• The FDA AUDACITY trial data could lead to entry into the large U.S. market.
• Allurion is leveraging the tailwinds from GLP-1 drugs.
• The Allurion balloon has a lower serious adverse event rate compared to other liquid-filled balloons.
• The company's virtual care suite provides an additional revenue stream.
• The Allurion program has shown positive early clinical results in diabetic and pre-diabetic patients.

Negatives

• The company's 2023 revenue was impacted by macroeconomic headwinds and destocking.
• The Allurion balloon is not yet approved for sale in the United States.
• The company is currently loss-making and is implementing cost reductions to reduce cash burn.
• The company is reliant on regulatory approvals for its products, including the gastric balloon in the U.S.

Risks

• The company's future performance is subject to risks and uncertainties, including its ability to acquire new customers and distributors.
• The company's ability to launch new products and obtain regulatory approvals is not guaranteed.
• The company faces competition from existing competitors and new market entrants.
• The company's reliance on its senior management team and its ability to retain skilled personnel is a risk.
• Economic and industry trends, such as fluctuating interest rates and rising inflation, could impact the company.
• Global pandemics, health crises, and political conflicts could also affect the company's business.

Future Outlook

Allurion is focused on sustainable growth and profitability, expanding into the U.S. market, scaling its virtual care suite, and leveraging GLP-1 tailwinds.

Management Comments

• Management believes Allurion is well-positioned for growth in 2024 and beyond.
• Management is targeting a 20% year-over-year growth in procedure volume for 2024.
• Management is implementing strategic cost reductions to reduce cash burn.

Industry Context

The announcement comes amid growing interest in weight management solutions, fueled by the adoption of GLP-1 drugs and a large addressable market for obesity treatments. Allurion is positioning itself as a unique solution with its procedureless balloon and digital platform.

Comparison to Industry Standards

• The Allurion balloon is presented as a less invasive alternative to bariatric surgery, which can cost between $14,000 and $33,000.
• The company claims a 10x lower serious adverse event rate compared to other liquid-filled balloons like Orbera and ReShape, although these were not compared in head-to-head studies.
• The Allurion balloon's intolerance rate is approximately 13%, which is lower than the 14-17% reported for 12-month endoscopic balloons.
• The company is targeting a $54 billion obesity treatment market by 2030, which is driven by GLP-1 drug adoption and growing interest in weight management solutions.
• The company is competing with other weight loss therapies, including bariatric surgery and other existing balloons, which have limitations in terms of invasiveness, cost, and patient experience.

Stakeholder Impact

• Shareholders will be impacted by the capital raise and the company's future performance.
• Employees will be impacted by the company's growth and cost reduction efforts.
• Customers will benefit from the company's innovative weight loss solutions.
• Suppliers will be impacted by the company's growth and demand for its products.
• Creditors will be impacted by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue to enroll patients in the AUDACITY trial.
• The company will continue to commercialize its AI-powered digital platform.
• The company will continue to expand its global presence.
• The company will continue to seek regulatory approvals for its products.
• The company will continue to implement cost reduction measures.

Key Dates

Keywords

Allurion, gastric balloon, weight loss, obesity, digital health, FDA, clinical trials, capital raise, GLP-1, virtual care